Back to top
more

Boston Scientific (BSX)

(Real Time Quote from BATS)

$104.06 USD

104.06
4,516,085

-0.77 (-0.74%)

Updated Aug 6, 2025 01:24 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value C Growth B Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (148 out of 246)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Headquartered in Natick, MA and founded in 1979, Boston Scientific Corporation manufactures medical devices and products used in various interventional medical specialties worldwide. The company has adopted the organic as well as inorganic routes for success. Boston Scientific currently has 3 global reportable segments viz. Cardiovascular (39.6% of total revenue in 2019; up 10% organically from 2018), Rhythm and Neuro (28.1%; up 1%) and MedSurg (30.2%; up 10.6%).

Zacks Equity Research

Millipede to Aid Boston Scientific, LOTUS Relaunch Lag Ails

by Zacks Equity Research

Boston Scientific's (BSX) major Millipede investment might cement the company's position in the emerging mitral regurgitation field under its structural heart business.

    Zacks Equity Research

    Boston Scientific's (BSX) Q4 Earnings In Line, Sales Top

    by Zacks Equity Research

    Boston Scientific (BSX) has posted impressive fourth quarter results by delivering revenue growth across all segments in Q4.

      Zacks Equity Research

      Medical Device Stocks Earnings Due on Feb 1: BSX, BAX & More

      by Zacks Equity Research

      As part of the amended tax policy, corporate tax rates are lowered to 21% from 35%, offering a huge relief to medical device giants.

        Zacks Equity Research

        Boston Scientific's (BSX) Millipede Deal Aids MR Business

        by Zacks Equity Research

        Boston Scientific (BSX) claims the Millipede IRIS annuloplasty ring to be highly customizable to a specific patient's anatomy and disease state.

          Zacks Equity Research

          Will WATCHMAN Boost Boston Scientific's (BSX) Q4 Earnings?

          by Zacks Equity Research

          Boston Scientific (BSX) witnesses improvement in IC arm on an innovative portfolio and robust commercial teams. The WATCHMAN platform is likely to impress with another solid quarterly performance.

            Zacks Equity Research

            Boston Scientific's Positive SCS Trial Aids Neuromodulation

            by Zacks Equity Research

            Boston Scientific's (BSX) WHISPER RCT data demonstrates that sub-perception and paresthesia-based SCS therapies deliver superior results when applied as a combo regimen.

              Zacks Equity Research

              Boston Scientific Fortifies Pain Therapy Arm With FDA Nod

              by Zacks Equity Research

              Boston Scientific (BSX) claims its Spectra WaveWriter Spinal Cord Stimulator System to combine both paresthesia-based and sub-perception therapies to target a specific area of pain.

                Zacks Equity Research

                MedTech Tax Resumes in 2018, 3 Stocks to Suffer

                by Zacks Equity Research

                Sectors that are likely to be hampered the most by the re-imposition of the medical device tax are X-ray and MRI machines, surgical instruments and pacemakers.

                  Zacks Equity Research

                  Boston Scientific Rises 8.3% on Upbeat 4Q Preliminary Sales

                  by Zacks Equity Research

                  Boston Scientific (BSX) pulls out all the stops to strengthen its core business as well as invest more in the global markets. This also gets reflected in its preliminary sales results.

                    Zacks Equity Research

                    Boston Scientific (BSX) Surges: Stock Moves 8.3% Higher

                    by Zacks Equity Research

                    Boston Scientific (BSX) saw a big move last session, as its shares jumped more than 8% on the day, amid huge volumes.

                      Zacks Equity Research

                      New Products Aid Boston Scientific, LOTUS Relaunch Lag Ails

                      by Zacks Equity Research

                      Boston Scientific (BSX) grows on product launches and international expansion. LOTUS relaunch delay hurts sales.

                        Zacks Equity Research

                        Boston Scientific Receives FDA Nod for Vercise DBS System

                        by Zacks Equity Research

                        Boston Scientific (BSX) forges ahead with initiatives to boost DBS portfolio under Neuromodulation business.

                          Zacks Equity Research

                          Boston Scientific (BSX) Shares Drop on LOTUS Relaunch Delay

                          by Zacks Equity Research

                          Boston Scientific (BSX) announces a delay in deadline for the commercial return of the LOTUS Edge Aortic Valve System in Europe. Following this news, share price declines.

                            Zacks Equity Research

                            The Zacks Analyst Blog Highlights: Baxter International, BostonScientific, Intuitive Surgical and Becton and Dickinson

                            by Zacks Equity Research

                            The Zacks Analyst Blog Highlights: Baxter International, BostonScientific, Intuitive Surgical and Becton and Dickinson

                              Zacks Equity Research

                              Trump Focuses on APAC: 4 MedTech Stocks to Watch

                              by Zacks Equity Research

                              Considering Trump's growing focus on APAC, the region seems to be poised to yield accretive returns over the long term. Favorable MedTech trends in APAC hold promise.

                                Zacks Equity Research

                                Boston Scientific's (BSX) Q3 Earnings In Line, Sales Top

                                by Zacks Equity Research

                                Boston Scientific (BSX) has posted impressive Q3 results by delivering revenue growth across all segments.

                                  Zacks Equity Research

                                  Zacks Industry Outlook Highlights: Johnson & Johnson, Abbott Labs, Medtronic and Boston Scientific.

                                  by Zacks Equity Research

                                  Zacks Industry Outlook Highlights: Johnson & Johnson, Abbott Labs, Medtronic and Boston Scientific.

                                    Zacks Equity Research

                                    MedTech Stock Q3 Earnings Roster for Oct 26: BSX, RMD & More

                                    by Zacks Equity Research

                                    Investors are concerned about the Medical sector that saw a lot of struggle during the first nine months of the year, thanks to the political change and the ongoing policy-restructuring related battle.

                                      Zacks Equity Research

                                      EW vs. BCR: Which Stock is Poised for Better Q3 Earnings?

                                      by Zacks Equity Research

                                      Political turmoil and the health policy related battle apart, majority of the MedTech stocks' bottom line is likely to be hurt in the third quarter on escalating costs induced by consecutive hurricanes and Mexico earthquakes.

                                        Zacks Equity Research

                                        Will Recall Issue Hurt Boston Scientific (BSX) Q3 Earnings?

                                        by Zacks Equity Research

                                        Although Boston Scientific's (BSX) recent $435-million acquisition of Symetis SA might drive its IC business, the company's full recovery post a primary product recall may however, take time.

                                          Zacks Equity Research

                                          Boston Scientific Grows on New Products, Currency Woe Ails

                                          by Zacks Equity Research

                                          Boston Scientific (BSX) is gaining traction on product launch and accretive acquisitions. Yet an unfavorable currency movement is a major dampener.

                                            Zacks Equity Research

                                            Boston Scientific's Apama Deal to Boost Electrophysiology Arm

                                            by Zacks Equity Research

                                            Boston Scientific's (BSX) Apama Medical addition is expected to strengthen its suite of arrhythmia solutions under the Electrophysiology sub-segment.

                                              Zacks Equity Research

                                              Abbott's Ellipse ICD Receives FDA Approval for MRI Scans

                                              by Zacks Equity Research

                                              Abbott's (ABT) Rhythm Management segment to gain traction with the latest FDA approval of Ellipse ICD for MR-conditioning labeling.

                                                Zacks Equity Research

                                                Boston Scientific's Resonate Devices Boost Cardiac Rhythm Arm

                                                by Zacks Equity Research

                                                Boston Scientific (BSX) is consistently strengthening its Cardiac Rhythm Management segment.

                                                  Zacks Equity Research

                                                  Medtronic (MDT) Initiates Study on CoreValve Evolut PRO TAVI

                                                  by Zacks Equity Research

                                                  Medtronic (MDT) to initiate FORWARD PRO Clinical Study for evaluating the safety standards of self-expanding TAVI system over longer-term.